Cargando…

Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo

Elderly and frail patients, diagnosed with acute myeloid leukemia (AML) and ineligible to undergo intensive treatment, have a dismal prognosis. The small molecule inhibitor volasertib induces a mitotic block via inhibition of polo-like kinase 1 and has shown remarkable anti-leukemic activity when co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schnerch, Dominik, Schüler, Julia, Follo, Marie, Felthaus, Julia, Wider, Dagmar, Klingner, Kathrin, Greil, Christine, Duyster, Justus, Engelhardt, Monika, Wäsch, Ralph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400573/ https://www.ncbi.nlm.nih.gov/pubmed/28416751 http://dx.doi.org/10.18632/oncotarget.15503

Ejemplares similares

The 3' Untranslated Region of the Cyclin B mRNA Is Not Sufficient to Enhance the Synthesis of Cyclin B during a Mitotic Block in Human Cells
por: Schnerch, Dominik, et al.
Publicado: (2013)

Suppression of APC/C(Cdh1) has subtype specific biological effects in acute myeloid leukemia
por: Ewerth, Daniel, et al.
Publicado: (2016)

Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma
por: Dold, Sandra Maria, et al.
Publicado: (2020)

Volasertib for AML: clinical use and patient consideration
por: Hao, Zhonglin, et al.
Publicado: (2015)

Intratibial Injection of Human Multiple Myeloma Cells in NOD/SCID IL-2Rγ(Null) Mice Mimics Human Myeloma and Serves as a Valuable Tool for the Development of Anticancer Strategies
por: Schueler, Julia, et al.
Publicado: (2013)

Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients
por: Riebl, Veronika, et al.
Publicado: (2021)

Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia
por: Adachi, Yoshiya, et al.
Publicado: (2017)

Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma
por: Waldschmidt, Johannes M., et al.
Publicado: (2022)

Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life
por: Greil, Christine, et al.
Publicado: (2019)

Proteasome inhibition: the dawn of novel therapies in multiple myeloma
por: Engelhardt, Monika, et al.
Publicado: (2022)

Strategic and Statistical Considerations on the QT Assessment of Volasertib
por: Wallenstein, Gudrun, et al.
Publicado: (2017)

Volasertib preclinical activity in high-risk hepatoblastoma
por: Kats, Dina, et al.
Publicado: (2019)

The role of the proteasome in AML
por: Csizmar, C M, et al.
Publicado: (2016)

The Role of the APC/C and Its Coactivators Cdh1 and Cdc20 in Cancer Development and Therapy
por: Greil, Christine, et al.
Publicado: (2022)

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
por: Waldeck, Silvia, et al.
Publicado: (2020)

Allogeneic Stem Cell Transplantation in Multiple Myeloma
por: Greil, Christine, et al.
Publicado: (2021)

Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab
por: Strüßmann, Tim, et al.
Publicado: (2022)

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
por: Gjertsen, B T, et al.
Publicado: (2015)

Correction to: Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
por: Greil, C., et al.
Publicado: (2021)

Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
por: Greil, C., et al.
Publicado: (2020)

Geriatric assessments and frailty scores in multiple myeloma patients: a needed tool for individualized treatment?
por: Möller, Mandy-Deborah, et al.
Publicado: (2021)

Volasertib Enhances Sensitivity to TRAIL in Renal Carcinoma Caki Cells through Downregulation of c-FLIP Expression
por: Jeon, Mi-Yeon, et al.
Publicado: (2017)

The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells
por: Dong, Jianwen, et al.
Publicado: (2018)

Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
por: Javorniczky, Nora Rebeka, et al.
Publicado: (2023)

Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia
por: Kobayashi, Yukio, et al.
Publicado: (2015)

The impact of pulmonary function in patients undergoing autologous stem cell transplantation
por: Duque-Afonso, Jesús, et al.
Publicado: (2021)

A Telomere Dependent DNA Damage Checkpoint Induced by Prolonged Mitotic Arrest
por: Hayashi, Makoto T., et al.
Publicado: (2012)

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011)

Conserved Mitotic Phosphorylation of a Proteasome Subunit Regulates Cell Proliferation
por: Duan, Jinyuan, et al.
Publicado: (2021)

Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status
por: Van den Bossche, Jolien, et al.
Publicado: (2019)

Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial
por: Döhner, Hartmut, et al.
Publicado: (2021)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML
por: Charlet, Anne, et al.
Publicado: (2021)

First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience
por: Kreutmair, Stefanie, et al.
Publicado: (2022)

The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation
por: Meier, Ruth, et al.
Publicado: (2022)

Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas
por: Murga-Zamalloa, Carlos, et al.
Publicado: (2017)

Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis
por: Rettig, Andrés R., et al.
Publicado: (2021)

Prolonged mitotic arrest induced by Wee1 inhibition sensitizes breast cancer cells to paclitaxel
por: Lewis, Cody W., et al.
Publicado: (2017)

Mitotic arrest affects clustering of tumor cells
por: Bonnet, Julia, et al.
Publicado: (2021)

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity
por: Awada, Ahmad, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7olt78d0moh5g3hh0msu2kr4hi